A blockade of PD-L1 produced antitumor and antimetastatic effects in an orthotopic mouse pancreatic cancer model via the PI3K/Akt/mTOR signaling pathway

References

• KamisawaTWoodLDItoiTTakaoriKPancreatic cancerLancet201638810039738526830752
   PubMed Web of Science ®Google Scholar
• AmundadottirLTPancreatic Cancer GeneticsInt J Biol Sci201612331432526929738
   PubMed Web of Science ®Google Scholar
• SiegelRMaJZouZJemalACancer statistics, 2014CA Cancer J Clin201464192924399786
   PubMed Web of Science ®Google Scholar
• RahibLSmithBDAizenbergRRosenzweigABFleshmanJMMatrisianLMProjecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United StatesCancer Res201474112913292124840647
   PubMed Web of Science ®Google Scholar
• KelegSBuchlerPLudwigRBuchlerMWFriessHInvasion and metastasis in pancreatic cancerMol Cancer200321412605717
   PubMedGoogle Scholar
• PardollDMThe blockade of immune checkpoints in cancer immunotherapyNat Rev Cancer201212425226422437870
   PubMed Web of Science ®Google Scholar
• FreemanGJLongAJIwaiYEngagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activationJ Exp Med200019271027103411015443
   PubMed Web of Science ®Google Scholar
• PedoeemAAzoulay-AlfaguterIStrazzaMSilvermanGJMorAProgrammed death-1 pathway in cancer and autoimmunityClin Immunol2014153114515224780173
   PubMed Web of Science ®Google Scholar
• BallyAPAustinJWBossJMGenetic and epigenetic regulation of PD-1 expressionJ Immunol201619662431243726945088
   PubMed Web of Science ®Google Scholar
• OkazakiTChikumaSIwaiYFagarasanSHonjoTA rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical applicationNat Immunol201314121212121824240160
   PubMed Web of Science ®Google Scholar
• FranciscoLMSagePTSharpeAHThe PD-1 pathway in tolerance and autoimmunityImmunol Rev201023621924220636820
   PubMed Web of Science ®Google Scholar
• OkazakiTMaedaANishimuraHKurosakiTHonjoTPD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosineProc Natl Acad Sci U S A20019824138661387111698646
   PubMed Web of Science ®Google Scholar
• SwaikaAHammondWAJosephRWCurrent state of anti-PD-L1 and anti-PD-1 agents in cancer therapyMol Immunol2015672 Pt A41725749122
   PubMedGoogle Scholar
• PatelSPKurzrockRPD-L1 Expression as a predictive biomarker in cancer immunotherapyMol Cancer Ther201514484785625695955
   PubMed Web of Science ®Google Scholar
• BrahmerJRTykodiSSChowLQSafety and activity of anti-PD-L1 antibody in patients with advanced cancerN Engl J Med2012366262455246522658128
   PubMed Web of Science ®Google Scholar
• SunshineJTaubeJMPD-1/PD-L1 inhibitorsCurr Opin Pharmacol201523323826047524
   PubMed Web of Science ®Google Scholar
• ParsaATWaldronJSPannerALoss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in gliomaNat Med2007131848817159987
   PubMed Web of Science ®Google Scholar
• YokosukaTTakamatsuMKobayashi-ImanishiWHashimoto-TaneAAzumaMSaitoTProgrammed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2J Exp Med201220961201121722641383
   PubMed Web of Science ®Google Scholar
• BaerRCintasCThervilleNGuillermet-GuibertJImplication of PI3K/Akt pathway in pancreatic cancer: When PI3K isoforms matter?Adv Biol Regul201559193526166735
   PubMedGoogle Scholar
• MayerIAArteagaCLThe PI3K/AKT Pathway as a Target for Cancer TreatmentAnn Rev Med201667112826473415
   PubMed Web of Science ®Google Scholar
• YothaisongSDokduangHTechasenAIncreased activation of PI3K/AKT signaling pathway is associated with cholangiocarcinoma metastasis and PI3K/mTOR inhibition presents a possible therapeutic strategyTumour Biol20133463637364823832540
   PubMedGoogle Scholar
• AdyaRTanBKPunnAChenJRandevaHSVisfatin induces human endothelial VEGF and MMP-2/9 production via MAPK and PI3K/Akt signalling pathways: novel insights into visfatin-induced angiogenesisCardiovasc Res200878235636518093986
   PubMed Web of Science ®Google Scholar
• BloomstonMZervosEERosemurgyAS2ndMatrix metalloproteinases and their role in pancreatic cancer: a review of preclinical studies and clinical trialsAnn Surg Oncol20029766867412167581
   PubMed Web of Science ®Google Scholar
• HartwigWWernerJJagerDDebusJBuchlerMWImprovement of surgical results for pancreatic cancerLancet Oncol20131411e476e48524079875
   PubMed Web of Science ®Google Scholar
• ZouYLiJChenZmiR-29c suppresses pancreatic cancer liver metastasis in an orthotopic implantation model in nude mice and affects survival in pancreatic cancer patientsCarcinogenesis201536667668425863127
   PubMed Web of Science ®Google Scholar
• OkudairaKHokariRTsuzukiYBlockade of B7-H1 or B7-DC induces an anti-tumor effect in a mouse pancreatic cancer modelInt J Oncol200935474174919724910
   PubMed Web of Science ®Google Scholar
• SmithJRobidaMDAcostaKQuantitative and qualitative characterization of Two PD-L1 clones: SP263 and E1L3NDiagn Pathol20161114427189072
   PubMedGoogle Scholar
• CaoYWangQDuYl-arginine and docetaxel synergistically enhance anti-tumor immunity by modifying the immune status of tumor-bearing miceInt Immunopharmacol20163571427003114
   PubMedGoogle Scholar
• HeLWuYLinLHispidulin, a small flavonoid molecule, suppresses the angiogenesis and growth of human pancreatic cancer by targeting vascular endothelial growth factor receptor 2-mediated PI3K/Akt/mTOR signaling pathwayCancer Sci2011102121922521087351
   PubMedGoogle Scholar
• VargovaVPytliakMMechirovaVMatrix metalloproteinasesEXS201210313322642188
   PubMedGoogle Scholar
• JakubowskaKPryczyniczAJanuszewskaJExpressions of matrix metalloproteinases 2, 7, and 9 in carcinogenesis of pancreatic ductal adenocarcinomaDis Markers20162016989572127429508
   PubMed Web of Science ®Google Scholar
• PostowMACallahanMKWolchokJDImmune checkpoint blockade in cancer therapyJ Clin Oncol201533171974198225605845
   PubMed Web of Science ®Google Scholar
• RileyJLPD-1 signaling in primary T cellsImmunol Rev2009229111412519426218
   PubMed Web of Science ®Google Scholar
• NomiTShoMAkahoriTClinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancerClin Cancer Res20071372151215717404099
   PubMed Web of Science ®Google Scholar
• MuenstSSchaerliARGaoFExpression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancerBreast Cancer Res Treat20141461152424842267
   PubMed Web of Science ®Google Scholar
• OhigashiYShoMYamadaYClinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancerClin Cancer Res20051182947295315837746
   PubMed Web of Science ®Google Scholar
• ZouWWolchokJDChenLPD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinationsSci Transl Med20168328328rv4
   PubMed Web of Science ®Google Scholar
• ZhangYZhangJXuKPTEN/PI3K/mTOR/B7-H1 signaling pathway regulates cell progression and immuno-resistance in pancreatic cancerHepatogastroenterology2013601271766177224624456
   PubMedGoogle Scholar
• OcanaAVera-BadilloFAl-MubarakMActivation of the PI3K/mTOR/AKT pathway and survival in solid tumors: systematic review and meta-analysisPLoS One201494e9521924777052
   PubMed Web of Science ®Google Scholar
• PolivkaJJrJankuFMolecular targets for cancer therapy in the PI3K/AKT/mTOR pathwayPharmacol Ther2014142216417524333502
   PubMed Web of Science ®Google Scholar
• BurrisHA3rdOvercoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathwayCancer Chemother Pharmacol201371482984223377372
   PubMed Web of Science ®Google Scholar
• AkinleyeAAvvaruPFurqanMSongYLiuDPhosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeuticsJ Hematol Oncol2013618824261963
   PubMedGoogle Scholar
• MaattaMSoiniYLiakkaAAutio-HarmainenHDifferential expression of matrix metalloproteinase (MMP)-2, MMP-9, and membrane type 1-MMP in hepatocellular and pancreatic adenocarcinoma: implications for tumor progression and clinical prognosisClin Cancer Res2000672726273410914717
   PubMed Web of Science ®Google Scholar